Index of estimated benefit from lymph node dissection for stage I-III transverse colon cancer: an analysis of the JS']JSCCR database

被引:1
|
作者
Sawayama, Hiroshi [1 ]
Miyamoto, Yuji [1 ]
Ogawa, Katsuhiro [1 ]
Ohuchi, Mayuko [1 ]
Tokunaga, Ryuma [1 ]
Yoshida, Naoya [1 ]
Kobayashi, Hirotoshi [2 ]
Sugihara, Kenichi [3 ]
Baba, Hideo [1 ]
机构
[1] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan
[2] Teikyo Univ, Sch Med, Mizonokuchi Hosp, Dept Surg, Kawasaki, Kanagawa, Japan
[3] Tokyo Med & Dent Univ, Tokyo, Japan
关键词
Transverse colon cancer; Lymph node dissection; Survival; IEBLD; COMPLETE MESOCOLIC EXCISION; RESECTION; LIGATION; SURGERY;
D O I
10.1007/s00423-022-02525-5
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose Main lymph node metastasis (LNM) dissection of transverse colon (TC) cancer is a difficult surgical procedure. Nonetheless, the main LNM ratio and the benefit of main lymph node (LN) dissection in TC cancer were unclear. This study aimed to identify high-risk patients for LNM and to evaluate the benefit of LN dissection in TC cancer. Methods Data for 26,552 colorectal cancer patients between 2007 and 2011 were obtained from the JSCCR database. Of these, 871 stage I-III TC cancer patients underwent surgery with radical LN dissection. These patients were evaluated using the index of estimated benefit from lymph node dissection (IEBLD), where IEBLD = (LNM ratio of each LN station) x (5-year overall survival (OS) rate of the patients with LNM) x 100. Results None of the patients with depth of invasion pT1-2 had main LNM. The presence of main LNM was associated with depth of invasion pT4, CEA-4H (carcinoembryonic antigen 4 times higher than preoperative cutoff value), or type 3, and 323 patients (37.1%) who had these factors were high-risk patients for main LNM. In these high-risk patients, the LNM ratio, 5-year OS rate of patients with LNM and IEBLD values, respectively, were 43.9%, 70.3%, and 30.5 for the pericolic LN; 20.3%, 66.0%, and 15.1 for the intermediate LN; and 9.6%, 58.5%, and 5.6 for the main LN. Conclusion Main LNM is associated with depth of invasion pT4, CEA-4H, or type 3. The IEBLD for the main LN of high-risk TC cancer patients was over 5.
引用
收藏
页码:2011 / 2019
页数:9
相关论文
共 50 条
  • [41] Benefit from adjuvant chemoradiation to resected stage IIIC gastric cancer patients with D2 lymph node dissection
    Peng, Jin
    Zhou, Fuxiang
    Dai, Jing
    Zhong, Yahua
    Xie, Conghua
    Qin, Yu'e
    Gong, Jun
    Xiong, Bing
    Zhou, Yunfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Effect of Age in Young Women With Stage I-III Triple-Negative Breast Cancer: A Report From the National Cancer Database
    Sittig, M.
    David, J.
    Yoshida, E. J.
    Reznik, R.
    McArthur, H. L.
    Chung, A.
    Mita, M.
    Amersi, F.
    Giuliano, A. E.
    Cook-Wiens, G.
    Shiao, S. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E46 - E47
  • [43] Surgical outcomes and predictors of overall survival of stage I-III appendiceal adenocarcinoma: Retrospective cohort analysis of the national cancer database
    Emile, Sameh Hany
    Horesh, Nir
    Freund, Michael R.
    Silva-Alvarenga, Emanuela
    Garoufalia, Zoe
    Gefen, Rachel
    Wexner, Steven D.
    SURGICAL ONCOLOGY-OXFORD, 2024, 52
  • [44] Clinical characteristics and prognosis analysis of postoperative patients with stage I–III colon cancer based on SEER database
    Fuqiang Zhao
    Ying Sun
    Jingying Zhao
    Jie Ge
    Chunlei Zheng
    Kepeng Ning
    Clinical and Translational Oncology, 2024, 26 : 225 - 230
  • [45] PREOPERATIVE NEOADJUVANT CHEMOTHERAPY TO PREVENT DISTANT RECURRENCE IN STAGE I-III COLON CANCER PATIENTS AFTER CURATIVE RESECTION: WHO MIGHT HAVE BENEFIT?
    Chandrachamnong, P.
    Riansuwan, W.
    DISEASES OF THE COLON & RECTUM, 2020, 63 (06) : E279 - E279
  • [46] Clinical Calculator for Predicting Freedom From Recurrence After Resection of Stage I-III Colon Cancer in Patients With Microsatellite Instability
    Bektas, Ayyuce Begum
    Hakki, Lynn
    Khan, Asama
    Widmar, Maria
    Wei, Iris H.
    Pappou, Emmanouil
    Smith, J. Joshua
    Nash, Garrett M.
    Paty, Philip B.
    Garcia-Aguilar, Julio
    Cercek, Andrea
    Stadler, Zsofia
    Segal, Neil H.
    Shia, Jinru
    Gonen, Mithat
    Weiser, Martin R.
    JCO CLINICAL CANCER INFORMATICS, 2024, 8
  • [47] The Prognostic Relevance of Sentinel Lymph Node Metastases Assessed by PHGR1 mRNA Quantification in Stage I to III Colon Cancer
    Oltedal, Satu
    Korner, Hartwig
    Aasprong, Ole Gunnar
    Hussain, Israr
    Tjensvoll, Kjersti
    Smaaland, Rune
    Soreide, Jon Arne
    Soreide, Kjetil
    Lothe, Ragnhild A.
    Heikkila, Reino
    Gilje, Bjornar
    Nordgard, Oddmund
    TRANSLATIONAL ONCOLOGY, 2018, 11 (02): : 436 - 443
  • [48] Local vs radical resection of stage I-III rectal cancer in very elderly patients: an exact matched analysis of the National Cancer Database
    Gefen, Rachel
    Emile, Sameh Hany
    Garoufalia, Zoe
    Horesh, Nir
    Dourado, Justin
    Wexner, Steven D.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 28 (08) : 1259 - 1264
  • [49] The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis
    Danish, Hasan H.
    Patel, Kirtesh R.
    Switchenko, Jeffrey M.
    Gillespie, Theresa W.
    Jhaveri, Jaymin
    Chowdhary, Mudit
    Abugideiri, Mustafa
    Delman, Keith A.
    Lawson, David H.
    Khan, Mohammad K.
    MELANOMA RESEARCH, 2016, 26 (06) : 595 - 603
  • [50] Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients
    Margalit, Ofer
    Boursi, Ben
    Rakez, Manel
    Thierry, Andre
    Yothers, Greg
    Wolmark, Norman
    Haller, Daniel G.
    Schmoll, Hans-Joachim
    Shi, Qian
    Shacham-Shmueli, Einat
    de Gramont, Aimery
    CLINICAL COLORECTAL CANCER, 2021, 20 (02) : 130 - 136